About 200 reports

  • 3.4.3 Forecast Assumptions and Methods - One-Year Total Prevalent Cases of POUD
  • Risk Factors and Comorbid Conditions Associated with OUD

The Han study provided the data for one-year total prevalence of DSM-IV opioid dependence.

  • Epidemiology
  • Hospital
  • Opioid
  • United States
  • Forecast

Opioid Drugs: Global Markets to 2023 Chapter ## Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report Information Sources Methodology Geographic Breakdown Analyst’s Credentials BCC Custom Research Related BCC Research Reports Chapter ## Summary and High

  • Opioid
  • Therapy
  • World
  • Market Shares

Global Opioids Drug Market Forecast 2019-2027 ##.

  • Opioid
  • Pharmaceutical
  • Therapy
  • World

GLOBAL NON-OPIOID PAIN TREATMENT MARKET FORECAST 2018-2026 ##.

  • Opioid
  • Therapy
  • World
  • Forecast
  • Market Size

Non-opioid Pain Treatment: Global Markets to 2022 Chapter ##: Introduction ## Study Goals and Objectives ## Reasons for Doing This Study ## Scope of Report ## Information Sources ## Methodology ## Geographic Breakdown ## Analyst’s Credentials ## Related B

  • Analgesic
  • Opioid
  • Therapy
  • World
  • Market Shares

Non-opioid Pain Patch Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 ##.

  • Opioid
  • Pharmaceutical
  • Therapy
  • World
  • Forecast

EUROPE OPIOIDS DRUG MARKET FORECAST 2019-2027 ##.

  • Opioid
  • Pharmaceutical
  • Therapy
  • Europe
  • Forecast

ASIA PACIFIC OPIOIDS DRUG MARKET FORECAST 2019-2027 ##.

  • Opioid
  • Pharmaceutical
  • Therapy
  • APAC
  • Forecast

NORTH AMERICA OPIOIDS DRUG MARKET FORECAST 2019-2027 ##.

  • Opioid
  • Pharmaceutical
  • Therapy
  • North America
  • A COMPARISON OF OPIOID AND NON-OPIOID DRUGS
  • PRIMARY ROUTES OF OPIOID ABUSE

ZACHAROFF, THIS COULD BE ONE OF THE PRIMARY REASONS FOR THE OPIOID EPIDEMIC. ##. ##. ##. ##.

  • Opioid
  • North America
  • United States
  • Eli Lilly & Co.
  • Grunenthal GmbH
  • ADVICE FOR THE TECHNOLOGY BUYER
  • Data Access and Sharing

IDC ANALYZE THE FUTURE IDC PERSPECTIVE Adelaide O' Brien EXECUTIVE SNAPSHOT FIGURE ## Addiction Prevention and Monitoring: Leveraging DX to Tackle the Opioid Epidemic in Kentucky Executive Snapshot: Addiction Prevention and Monitoring - Leveraging DX to Tackle the

  • Advanced IT
  • Healthcare
  • Opioid
  • Therapy
  • United States

2019 Future of Opioid/ Opium Addiction R& D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments ##.

  • Opioid
  • Therapy

Global Market Study on Opioids: Widespread Usage in Treatment of Cancer to Drive the Growth of Opioids Market During the Forecast Period ##.

  • Opioid
  • Therapy
  • APAC
  • World
  • Market Size

One of the major determinants is the growing geriatric population with clinically demonstrated susceptibility to terminal conditions, such as rheumatoid arthritis, is positively impacting this vertical.

  • Opioid
  • Therapy
  • North America
  • United States
  • Forecast
  • JUN 19, 2018: METHADONE AND BUPRENORPHINE REDUCE RISK OF DEATH AFTER OPIOID OVERDOSE
  • JUN 22, 2018: ANALYSIS OF INSURANCE COVERAGE FOR BACK PAIN SHOWS MISSED OPPORTUNITIES TO PRESCRIBE NON-OPIOID MEDICATIONS

" Opioid addiction has emerged as one of the most critical public health issues, said Dr.

  • Opioid
  • Therapy
  • United States
  • Lightlake Therapeutics Inc.
  • Opiant Pharmaceuticals, Inc.
  • OPIOID PRESCRIPTIONS
  • ADVANCES IN OPIOID RECEPTOR RESEARCH

BUNAVAIL CONTAINS BUPRENORPHINE HCL, A MU--OPIOID RECEPTOR PARTIAL AGONIST AND A KAPPA--OPIOID RECEPTOR ANTAGONIST, AND NALOXONE HCL DIHYDRATE, AN OPIOID RECEPTOR ANTAGONIST, AT A RATIO OF ~##:## (RATIO OF FREE BASES).

  • Opioid
  • Actavis plc
  • Bedrocan Canada Inc.
  • Insys Therapeutics, Inc.
  • Medical Marijuana, Inc.
  • 3. Opioid Dependence Market
  • 1.5 OPIOIDS OVERVIEW

In the U. S., there are indications of a partial shift in the use of opioids towards heroin, attributable in the part to changes in the formulation of OxyContin, which is one of the main prescription opioids to be misused.

  • Opioid
  • United States
  • Egalet Corporation
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • NON-GOVERNMENT INSTITUTIONS INITIATIVES
  • 9.4 INCREASED PRODUCTION AND TRAFFICKING OF ILLEGAL DRUGS

The overdose of opioids results in adverse and serious health conditions.

  • Opioid
  • World
  • Forecast
  • Alere Inc.
  • Danaher Corporation
  • Opioids
  • Opioids

You can easily book an appointment with one online.

  • Opioid
  • Market Size
  • BioDelivery Sciences International, Inc.
  • ProStrakan Group plc
  • Teva Pharmaceuticals Ltd.
  • 3.2 Opioid Sales in US Chronic Pain Market - Forecast: Sizing &
  • 3.1 Opioid Sales in US Chronic Pain Market: Sizing & Growth

The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-##) November 2014 Daedal Research List of Figures and Tables ##.

  • Opioid
  • United States
  • Egalet Corporation
  • Pfizer Inc.
  • Zogenix, Inc.

Since the availability of ADF opioids have you become more reluctant to prescribe generic opioids which do not have an ADF?

  • Opioid
  • Pharmaceutical
  • Therapy
  • United States

•Moderate to severe chronic pain therapeutics market is the most mature one and the largest opioid market segment, holding nearly x % of the market share.

  • Opioid
  • Therapy
  • United States
  • Demand
  • Market Size
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Product Development Milestones
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products

It binds to opioid receptor like ## (ORL-##, NOC-##) receptor.

  • Opioid
  • Therapy
  • United States
  • World
  • Product Initiative
  • Opium (Opioid) Addiction - Therapeutics Assessment
  • Opium (Opioid) Addiction - Discontinued Products

Opium (Opioid) Addiction - Overview Opium (Opioid) Addiction - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR OPIUM (OPIOID) ADDICTION, H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR OPIUM (OPIOID) ADDICTION, H## 2018 Pre-Regi

  • Opioid
  • Therapy
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd
  • Opioid-Induced Constipation (OIC) - Drug Profiles
  • Opioid-Induced Constipation (OIC) - Therapeutics Assessment

The molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are ##, ## and ## respectively.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Opioid
  • United States
  • Product Initiative

Deciphering the commercial opportunity is one that analysts are yet to agree on fully.

  • Opioid
  • Therapy
  • United States
  • World
  • Demand
  • Opioid-Induced Constipation (OIC) - Therapeutics Assessment
  • Opioid-Induced Constipation (OIC) - Product Development Milestones

All doses were safe and well tolerated with only four serious adverse events reported (## for placebo, ## for the ##. ## mg and ## for the ##. ## mg dose groups).

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Opioid
  • United States
  • Product Initiative
  • Opium (Opioid) Addiction - Therapeutics Assessment
  • Mu Type Opioid Receptor Agonist

" Opioid addiction is one of the worst public health crises in our nation' s history.

  • Opioid
  • Therapy
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd
  • TOP COMPANIES PARTICIPATING IN OPIOID-INDUCED CONSTIPATION (OIC) THERAPEUTICS CLINICAL TRIALS
  • Brazil has the highest number of opioid-induced constipation (oic) clinical trials, as of April 2018.

OPIOID-INDUCED CONSTIPATION (OIC) THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2018* CLINICAL TRIALS BY END POINT STATUS OPIOID-INDUCED CONSTIPATION (OIC) THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2018* OPIOID-INDUCED CONSTIPATION (OIC) THERA

  • Clinical Trial
  • Gastrointestinal Drug
  • Opioid
  • World
  • Product Initiative
  • LATEST CLINICAL TRIALS NEWS ON OPIUM (OPIOID) ADDICTION
  • TOP COMPANIES PARTICIPATING IN OPIUM (OPIOID) ADDICTION THERAPEUTICS CLINICAL TRIALS

OPIUM (OPIOID) ADDICTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* OPIUM (OPIOID) ADDICTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* OPIUM (OPIOID) ADDICTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE,

  • Clinical Trial
  • Opioid
  • World
  • Product Initiative
  • Indivior PLC